目錄:MedChemExpress LLC>>信號通路>> KIRA-7 | MCE
CAS | 1937235-76-1 | 純度 | 98.33% |
---|---|---|---|
分子量 | 466.51 | 分子式 | C??H??FN?O |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mg |
貨號 | HY-124646 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
產(chǎn)品活性:KIRA-7 是一種咪唑并吡嗪化合物,,可與 IRE1α 激酶結(jié)合 (IC50 為 110 nM) 以變構(gòu)方式抑制其 RNase 活性,。KIRA-7 具有抗纖維化作用。
研究領(lǐng)域:Cell Cycle/DNA Damage
作用靶點:IRE1
In Vitro: KIRA-7 can inhibit XBP1 splicing in the alveolar epithelial cell line MLE12.
In Vivo: KIRA-7 (5 mg/kg; intraperitoneal injection; daily for 14 days; C57BL6 mice) treatment results in decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice treated with vehicle. Likewise, mRNA levels of BiP and CHOP are significantly elevated after Bleomycin exposure, and treatment of Bleomycin-exposed mice with KIRA-7 decreased these levels. mRNA levels of collagen 1A1 and fibronectin are both significantly decreased by KIRA-7 treatment.
相關(guān)產(chǎn)品:Covalent Screening Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | Anti-Aging Compound Library | Covalent Screening Library | Endoplasmic Reticulum Stress Compound Library | Toyocamycin | IRE1α kinase-IN-4 | 4μ8C | 3,6-DMAD hydrochloride | GSK2850163 (S enantiomer) | KIRA9 | IRE1α kinase-IN-6 | B I09 | Sunitinib | IRE1α kinase-IN-7 | KIRA6 | IXA6 | MKC3946 | IRE1α kinase-IN-1 | IRE1α kinase-IN-3 | IXA4 | MKC9989 | Kira8 Hydrochloride | 6-Bromo-2-hydroxy-3-methoxybenzaldehyde | MKC8866 | IRE1α kinase-IN-5 | GSK2850163 hydrochloride | STF-083010 | PAIR2
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物,;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng),;
• 產(chǎn)品種類涵蓋各種重組蛋白,,多肽,常用試劑盒 ,,更有 PROTAC,、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā),、生命科學(xué)等科研項目,;
• 提供虛擬篩選,離子通道篩選,,代謝組學(xué)分析檢測分析,,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控,、驗證體系,;
• 提供 LC/MS、NMR,、HPLC、手性分析,、元素分析等各項質(zhì)檢報告,,確保產(chǎn)品的高純度、高品質(zhì),;
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證,;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展,,為您提供*新的活性化合物,;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。
(空格分隔,最多3個,單個標(biāo)簽最多10個字符)